Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 14/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17778979 | 0.86 | SIGMAR1 (0.44) | MEN1SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL20090265 | 0.83 | SIGMAR1 (0.42) | MEN1SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL17778978 | 0.83 | SIGMAR1 (0.42) | MEN1SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL17768496 | 0.83 | SIGMAR1 (0.52) | SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL17768530 | 0.80 | SIGMAR1 (0.64) | SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL17778980 | 0.78 | SIGMAR1 (0.50) | MEN1SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL17779123 | 0.78 | SIGMAR1 (0.49) | SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL17779121 | 0.78 | SIGMAR1 (0.51) | SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL17778960 | 0.77 | PRMT5 (0.42) | MEN1SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL17778832 | 0.76 | SIGMAR1 (0.44) | MEN1SIGMAR1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407428-B2 | Spiro-isoquinoline-1,4′-piperidine compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-09-10 | — | — | US | disclosed |
| EP-3221314-B1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-07-03 | — | — | EP | disclosed |
| US-20180111935-A1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-04-26 | — | — | US | disclosed |
| US-20180111935-A1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-04-26 | — | — | US | disclosed |
| WO-2016078770-A1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407428-B2 | Spiro-isoquinoline-1,4′-piperidine compounds having multimodal activity against pain | OPRD1, OPRK1, OPRL1 | MEN1 4874/4885SIGMAR1 5/4885HTR2A 93/4885 |
| US-20180111935-A1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, OPRK1, OPRL1 | MEN1 4875/4885SIGMAR1 5/4885HTR2A 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.